Navigation Links
Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
Date:9/11/2008

ST. LOUIS, Sept. 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into an exclusive agreement with IsoSciences, LLC, to distribute isotopically labeled bioactive compounds and their metabolites (http://www.sigma-aldrich.com/isotope) through its Aldrich division. IsoSciences, a leading stable isotope company, provides a wide array of biological compounds and custom synthesis products. Aldrich, provider of ISOTEC(R) Stable Isotopes, is a leader in manufacturing and providing stable isotope products for biomolecular NMR, proteomics, metabolic and MRI research.

Under the terms of the agreement, IsoSciences will be the exclusive provider to Aldrich for their stable isotope products listed in the agreement. These products include deuterated, 13C and 15N labeled vitamins, steroids, and other bioactive compounds used in metabolic research.

Nutrition and metabolic research investigates the relationships among diet, health and diseases by nutrient interactions with various metabolic pathways, bioavailability and nutrient analysis. These stable isotope products will be an addition to the extensive list of unlabeled bioactive compounds provided by Sigma-Aldrich.

"A new partnership with IsoSciences will allow Sigma-Aldrich to provide new stable isotope product lines to support our customers' research," said Dr. C.T. Tan, ISOTEC Stable Isotope's R&D Manager. "This collaboration offers a new range of labeled bioactive compounds for our ever expanding customer base."

"We have invested heavily in synthesizing difficult-to-prepare, yet vitally needed, isotopically labeled standards," said David Saunders, President of IsoSciences, LLC.

IsoSciences' CEO Dr. Scott W. Landvatter added, "Our partnership with Sigma-Aldrich will allow us the widest possible distribution of our unique stable isotope labeled compounds to scientists worldwide."

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.

About IsoSciences: IsoSciences, LLC is a leader in providing custom synthesized isotopically labeled compounds including intermediates, final drug substances, and isotopically labeled biological standards. IsoSciences works with the world's leading pharmaceutical companies, diagnostic laboratories, medical researchers and other companies requiring stable-isotope labeled compounds for R&D. For more information about products and services offered by IsoSciences, LLC please visit http://www.isosciences.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich, Aldrich and ISOTEC are registered of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... ... 24, 2017 , ... FireflySci, Inc is an explosive small business that continues ... goal of bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy ... is going on as they add yet another mark on the global map. , ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
Breaking Biology News(10 mins):